Overdose and off-label psychotropic prescribing in patients with borderline personality disorder: A retrospective series.


Journal

Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists
ISSN: 1440-1665
Titre abrégé: Australas Psychiatry
Pays: England
ID NLM: 9613603

Informations de publication

Date de publication:
04 2023
Historique:
medline: 11 4 2023
pubmed: 12 2 2023
entrez: 11 2 2023
Statut: ppublish

Résumé

Borderline personality disorder (BPD) is common and poses many clinical challenges. Despite limited evidence of effectiveness, psychotropic medications are often prescribed. We aimed to characterise overdose presentations in patients with BPD. This is a retrospective observational series of patients with BPD presenting to a tertiary hospital following an overdose from January 2019 to December 2020. Medical records were reviewed to determine baseline characteristics, overdose details, clinical features, treatment, and disposition. There were 608 presentations in 370 people (76% female), median age 28 years (range 16-75 years). The majority (331[89%]) of patients were prescribed at least one psychotropic medication, with 129 (35%) being prescribed three or more different psychotropic agents. Of the total prescribed psychotropics, 520/1459 (36%) were for off-label indications. The majority of agents (860/1487[58%]) taken in overdose were prescribed. The commonest drug classes taken in overdose were benzodiazepines (241[16%]) and antipsychotics (229[15%]). Severe toxicity occurred in 99 (16%) cases with either coma (GCS<9) or hypotension (systolic BP <90 mmHg). The commonest agent associated with severe toxicity was quetiapine 39/99 (39%). Psychotropic polypharmacy is common in BPD, often with off-label indications. Prescribed medications are commonly taken in overdose. Quetiapine is over-represented both in off-label prescribing and associated harm.

Identifiants

pubmed: 36772817
doi: 10.1177/10398562231153009
pmc: PMC10088345
doi:

Substances chimiques

Quetiapine Fumarate 2S3PL1B6UJ
Psychotropic Drugs 0
Antipsychotic Agents 0

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

195-200

Références

J Clin Psychopharmacol. 2019 Jul/Aug;39(4):312-317
pubmed: 31205192
Innov Clin Neurosci. 2011 Sep;8(9):10-3
pubmed: 22010059
Int J Psychiatry Clin Pract. 2019 Sep;23(3):178-188
pubmed: 31140337
Br J Psychiatry. 2006 Apr;188:374-9
pubmed: 16582065
BMC Psychiatry. 2019 Dec 12;19(1):393
pubmed: 31830934
Cochrane Database Syst Rev. 2022 Nov 14;11:CD012956
pubmed: 36375174
Toxicol Rep. 2014 May 22;1:209-213
pubmed: 28962240
Hum Psychopharmacol. 2008 Jan;23 Suppl 1:43-51
pubmed: 18098225
J Clin Psychiatry. 2006 Jul;67(7):1042-6
pubmed: 16889446
Compr Psychiatry. 2001 Mar-Apr;42(2):144-50
pubmed: 11244151
Psychiatr Serv. 2019 Sep 1;70(9):772-781
pubmed: 31138059
Am J Psychiatry. 2014 Nov 1;171(11):1174-82
pubmed: 24968985
J Clin Psychopharmacol. 2015 Feb;35(1):63-7
pubmed: 25384261
Int J Psychiatry Clin Pract. 2011 Nov;15(4):280-5
pubmed: 22122000
Curr Psychiatry Rep. 2017 Mar;19(3):16
pubmed: 28271272
Soc Psychiatry Psychiatr Epidemiol. 2000 Dec;35(12):531-8
pubmed: 11213842
Am J Forensic Med Pathol. 2017 Dec;38(4):349-352
pubmed: 28795995
Curr Psychiatry Rep. 2015 Jan;17(1):534
pubmed: 25413640
J Pers Disord. 2021 Jun;35(3):321-335
pubmed: 31609189
Aust Prescr. 2016 Apr;39(2):49-53
pubmed: 27340322
Am J Psychiatry. 2000 Apr;157(4):601-8
pubmed: 10739420
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):158-63
pubmed: 17045720
Drug Alcohol Depend. 2018 Jun 1;187:95-99
pubmed: 29655032
CNS Drugs. 2021 Oct;35(10):1053-1067
pubmed: 34495494
Psychiatr Serv. 2010 Jun;61(6):612-6
pubmed: 20513685
CMAJ. 2021 Feb 1;193(5):E167-E170
pubmed: 33526543
Personal Ment Health. 2018 Nov;12(4):309-320
pubmed: 30094955
Am J Psychiatry. 2001 Feb;158(2):295-302
pubmed: 11156814
Am J Psychiatry. 2001 Oct;158(10 Suppl):1-52
pubmed: 11665545
Int Clin Psychopharmacol. 2010 Nov;25(6):349-55
pubmed: 20838221
Psychiatr Clin North Am. 2000 Mar;23(1):169-92, ix
pubmed: 10729938
J Clin Psychiatry. 2015 Apr;76(4):e512-8
pubmed: 25919844
Int J Psychiatry Clin Pract. 2017 Mar;21(1):75-79
pubmed: 27669762
Subst Abuse. 2015 May 24;9:39-46
pubmed: 26056465
Biol Psychiatry. 2002 Jun 15;51(12):936-50
pubmed: 12062877
J Med Case Rep. 2019 Feb 27;13(1):45
pubmed: 30808405
Eur Neuropsychopharmacol. 2015 Jun;25(6):763-72
pubmed: 25907249

Auteurs

Anna Y Ning (AY)

420004University of Queensland, Herston, Australia.

Theo Theodoros (T)

420004University of Queensland, Herston, Australia.
Emergency Department Mental Health, Princess Alexandra Hospital, Woolloongabba, Australia.

Keith Harris (K)

420004University of Queensland, Herston, Australia.
Clinical Toxicology Unit, Princess Alexandra Hospital, Woolloongabba, Australia.

Katherine Z Isoardi (KZ)

420004University of Queensland, Herston, Australia.
Clinical Toxicology Unit, Princess Alexandra Hospital, Woolloongabba, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH